Non-interventional Study of Risperidone ISM® in Schizophrenia Patients Hospitalised Due to a Relapse

CompletedOBSERVATIONAL
Enrollment

275

Participants

Timeline

Start Date

October 18, 2022

Primary Completion Date

March 13, 2025

Study Completion Date

March 13, 2025

Conditions
Schizophrenia
Interventions
DRUG

Risperidone ISM

Risperidone ISM is administered every 4 weeks

Trial Locations (77)

Unknown

Investigational site number DE-06, Aachen

Investigational site number DE-14, Ansbach

Investigational site number DE-23, Bayreuth

Investigational site number DE-10, Berlin

Investigational site number DE-12, Berlin

Investigational site number DE-15, Berlin

Investigational site number DE-07, Bonn

Investigational site number DE-16, Bonn

Investigational site number DE-02, Chemnitz

Investigational site number DE-03, Dortmund

Investigational site number DE-25, Eberswalde

Investigational Site number DE-01, Essen

Investigational site number DE-08, Greifswald

Investigational site number DE-22, Hamburg

Investigational site number DE-20, Hemer

Investigational site number DE-19, Leipzig

Investigational site number DE-05, Mannheim

Investigational site number DE-04, Munich

Investigational site number DE-09, München

Investigational site number DE-24, Neustadt

Investigational site number DE-13, Werneck

Investigational site number IT-32, Ancona

Investigational site number IT-19, Bolzano

Investigational site number IT-24, Brescia

Investigational site number IT-65, Brindisi

Investigational site number IT-20, Crema

Investigational site number IT-41, Foggia

Investigational site number IT-03, Legnano

Investigational site number IT-47, Manfredonia

Investigational site number IT-06, Milan

Investigational site number IT-42, Milan

Investigational site number IT-18, Montichiari

Investigational site number IT-113, Palermo

Investigational site number IT-44, Putignano

Investigational site number IT-97, Sant'Agata di Militello

Investigational site number IT-90, Vimercate

Investigational site number PT-25, Beja

Investigational site number PT-24, Braga

Investigational site number PT-01, Coimbra

Investigational site number PT-33, Funchal

Investigational site number PT-36, Funchal

Investigational site number PT-20, Guarda

Investigational site number PT-32, Portimão

Investigational site number PT-13, Porto

Investigational site number PT-11, Santo Tirso

Investigational site number PT-27, Tomar

Investigational site number ES-03, Barcelona

Investigational site number ES-45, Barcelona

Investigational site number ES-81, Barcelona

Investigational site number ES-16, Burgos

Investigational site number ES-23, Córdoba

Investigational site number ES-11, Granada

Investigational site number ES-59, Huesca

Investigational site number ES-21, Jaén

Investigational site number ES-70, Jerez de la Frontera

Investigational site number ES-72, L'Hospitalet de Llobregat

Investigational site number ES-60, Las Palmas de Gran Canaria

Investigational site number ES-49, Lleida

Investigational site number ES-51, Lugo

Investigational site number ES-19, Madrid

Investigational site number ES-24, Madrid

Investigational site number ES-66, Madrid

Investigational site number ES-63, Majadahonda

Investigational site number ES-04, Manacor

Investigational site number ES-73, Manresa

Investigational site number ES-65, Mataró

Investigational site number ES-14, Móstoles

Investigational site number ES-18, Murcia

Investigational site number ES-52, Ourense

Investigational site number ES-62, Ponferrada

Investigational site number ES-69, Santander

Investigational site number ES-02, Talavera de la Reina

Investigational site number ES-42, Torrejón

Investigational site number ES-76, Úbeda

Investigational site number ES-31, Vigo

Investigational site number ES-40, Vitoria-Gasteiz

Investigational site number GB-08, London

All Listed Sponsors
lead

Rovi Pharmaceuticals Laboratories

INDUSTRY